SLE ACTIVITY INDEX SCORE (SIS) FORM

2007 ◽  
pp. 555-555
Keyword(s):  
Activity Index ◽  
Index Score ◽  
Activity Index Score

scholarly journals Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis

2017 ◽  
Vol 23 (18) ◽  
pp. 3322 ◽  
Author(s):  
Basavaraj Kerur ◽  
Heather J Litman ◽  
Julia Bender Stern ◽  
Sarah Weber ◽  
Jenifer R Lightdale ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Young Adults ◽  
Disease Severity ◽  
Activity Index ◽  
Index Score ◽  
Children And Young Adults ◽  
Activity Index Score

scholarly journals Sleep disturbance as a moderator of the association between physical activity and later pain onset among American adults aged 50 and over: evidence from the Health and Retirement Study

BMJ Open ◽  
2020 ◽  
Vol 10 (6) ◽  
pp. e036219
Author(s):  
Daniel Whibley ◽  
Heidi M Guyer ◽  
Leslie M Swanson ◽  
Tiffany J Braley ◽  
Anna L Kratz ◽  
...  
Keyword(s):  
Physical Activity ◽  
Sleep Disturbance ◽  
Activity Index ◽  
Vigorous Physical Activity ◽  
Index Score ◽  
Health And Retirement Study ◽  
Physical Activity Index ◽  
Activity Index Score ◽  
Incident Pain ◽  
Retirement Study

ObjectiveTo examine whether sleep disturbance modifies the association between physical activity and incident pain.DesignProspective population-based study.SettingHealth and Retirement Study.ParticipantsAmerican adults aged ≥50 years who reported no troublesome pain in 2014 were re-assessed for pain in 2016. Of 9828 eligible baseline respondents, 8036 (82%) had complete follow-up data for adjusted analyses (weighted analysis population N=42 407 222).ExposuresPhysical activity was assessed via interview with questions about time spent in moderate and vigorous physical activity. Sleep disturbance, assessed using a modified form of the Jenkins Sleep Scale, was examined as a potential moderator.Main outcome measureTroublesome pain.ResultsIn weighted analyses, 37.9% of the 2014 baseline pain-free sample participated in moderate or vigorous physical activity once a week or less, with an overall mean Physical Activity Index Score of 9.0 (SE=0.12). 18.6% went on to report troublesome pain in 2016. Each one-point higher on the Physical Activity Index Score was associated with a reduced odds ratio (OR) of incident pain for those who endorsed sleep disturbance never/rarely (OR=0.97, 95% CI 0.94 to 0.99), but not for those who endorsed sleep disturbance sometimes (OR=0.99, 95% CI 0.97 to 1.01) or most of the time (OR=1.01, 95% CI 0.99 to 1.03). The analysis of possible interaction demonstrated that frequency of sleep disturbance moderated the physical activity and incident pain association (Wald test: p=0.02).ConclusionsThe beneficial association of physical activity on reduced likelihood of later pain was only observed in persons who endorsed low levels of sleep disturbance.

scholarly journals Beneficial Effect of Shikonin on Experimental Colitis Induced by Dextran Sulfate Sodium in Balb/C Mice

2012 ◽  
Vol 2012 ◽  
pp. 1-15 ◽  
Author(s):  
Isabel Andújar ◽  
José Luis Ríos ◽  
Rosa María Giner ◽  
José Miguel Cerdá ◽  
María del Carmen Recio
Keyword(s):  
Disease Activity ◽  
Activity Index ◽  
Disease Activity Index ◽  
Experimental Colitis ◽  
Myeloperoxidase Activity ◽  
Dependent Manner ◽  
Inflammatory Bowel ◽  
Activity Index Score ◽  
Bloody Stools ◽  
Dose Dependent

The naphthoquinone shikonin, a major component of the root ofLithospermum erythrorhizon, now is studied as an anti-inflammatory agent in the treatment of ulcerative colitis (UC). Acute UC was induced in Balb/C mice by oral administration of 5% dextran sodium sulfate (DSS). The disease activity index was evaluated, and a histologic study was carried out. Orally administered shikonin reduces induced UC in a dose-dependent manner, preventing the shortening of the colorectum and decreasing weight loss by 5% while improving the appearance of feces and preventing bloody stools. The disease activity index score was much lower in shikonin-treated mice than in the colitic group, as well as the myeloperoxidase activity. The expression of cyclooxygenase-2 was reduced by 75%, activation of NF-κB was reduced by 44%, and that of pSTAT-3 by 47%, as well as TNF-α, IL-1β, and IL-6 production. Similar results were obtained in primary macrophages culture. This is the first report of shikonin’s ability to attenuate acute UC induced by DSS. Shikonin acts by blocking the activation of two major targets: NF-κB and STAT-3, and thus constitutes a promising potential therapeutic agent for the management of the inflammatory bowel disease.

scholarly journals Reduced sB7-H3 Expression in the Peripheral Blood of Systemic Lupus Erythematosus Patients

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Jing Sun ◽  
Huijun Lai ◽  
Dong Shen ◽  
Pingping Wu ◽  
Jie Yang ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Peripheral Blood ◽  
Regulatory Networks ◽  
Activity Index ◽  
Disease Activity Index ◽  
Systemic Lupus ◽  
Aberrant Expression ◽  
Activity Index Score

Both membrane-bound and soluble forms of costimulatory molecules play important roles in immune-regulatory networks. B7-H3, a member of the B7 family, has been found with aberrant expression in tumors and infectious disease. However, the significance of sB7-H3 expression in systemic lupus erythematosus (SLE) has not been investigated. Using the peripheral blood of 78 SLE patients, we established a comprehensive database containing clinical data and relevant laboratory tests. We found that sB7-H3 expression in SLE patients was significantly lower compared with the healthy individuals. In addition, sB7-H3 levels in the patients were positively correlated with the disease activity as indicated by SLE disease activity index score, rashes, fever, and inflammatory cytokines. Moreover, sB7-H3 was associated with the counts of red blood cells and hemoglobin. Our findings suggest that sB7-H3 might counteract the aberrant immune response and potentially serve as a monitoring indicator of disease progression and therapeutic target in SLE treatment.

Sign in / Sign up

Export Citation Format

Share Document